Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 397

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma

Open access
Ricke, Jens, Klümpen, Heinz Josef, Amthauer, Holger, Bargellini, Irene, Bartenstein, Peter, de Toni, Enrico N., Gasbarrini, Antonio, Pech, Maciej, Peck-Radosavljevic, Markus, Popovič, Peter, Rosmorduc, Olivier, Schott, Eckart, Seidensticker, Max, Verslype, Chris, Sangro, Bruno, Malfertheiner, Peter · 2019 · Journal of Hepatology

Abstract

BACKGROUND Sorafenib is the recommended treatment for patients with advanced hepatocellular carcinoma (HCC). We aimed to compare the efficacy and safety of a combination of selective internal radiotherapy (SIRT) with yttrium-90 (90Y) resin microspheres and sorafenib with those of sorafenib alone in patients with advanced HCC. METHODS SORAMIC is a randomised controlled trial comprising diagnostic, local ablation and palliative cohorts. Based on diagnostic study results patients were assigned to local ablation or palliative cohorts. In the palliative cohort, patients not eligible for TACE were randomised 11:10 to SIRT plus sorafenib (SIRT+sorafenib) or sorafenib alone. The primary endpoint was overall survival (OS; Kaplan-Meier analysis) in the intention-to-treat (ITT) population. RESULTS In the ITT cohort, 216 patients were randomised to SIRT+sorafenib and 208 to sorafenib alone. Median OS was 12∙1 months in the SIRT+sorafenib arm, and 11∙4months in the sorafenib arm (hazard ratio [HR], 1∙01; 95% CI 0∙81-1∙25; p=0∙9529). Median OS in the per-protocol population, was 14∙0 months in the SIRT+sorafenib arm (n=114), and 11∙1months in the sorafenib arm (n=174; HR, 0∙86; p=0∙2515). Subgroup analyses of the PP population indicated a survival benefit of SIRT+sorafenib for patients without cirrhosis (HR, 0∙46, 0∙25-0∙86; p=0∙02); cirrhosis of non-alcoholic aetiology (HR, 0∙63, p=0∙012); or patients ≤65 years (HR, 0∙65, p=0∙05). Adverse events (AEs) of Common Terminology Criteria for AE Grades 3-4 were reported in 103/159 (64∙8%) patients who received SIRT+sorafenib, 106/197 (53∙8%) patients who received sorafenib only (p=0∙04), and 8/24 (33∙3%) patients who only received SIRT. CONCLUSION Addition of SIRT to sorafenib did not result in a significant improvement in OS compared with sorafenib alone. Subgroup analyses led to hypothesis-generating results supporting future study design. Funding Financial support by Sirtex Medical and Bayer Healthcare Lay summary Sorafenib given orally is the recommended treatment for patients with advanced hepatocellular carcinoma (HCC). In selective internal radiotherapy therapy (SIRT), also known as radioembolisation, microscopic, radioactive resin or glass spheres are introduced into the blood vessels that feed the tumours in the liver. This study found that the addition of SIRT with 90yttrium-loaded resin microspheres to sorafenib treatment in people with advanced HCC did not significantly improve overall survival compared with sorafenib treatment alone. However, the results suggest how future studies on this combination therapy in people with advanced HCC could be designed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhep.2019.08.006

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 397

Metadata

Authors
Ricke, J., Klümpen, H. J., Amthauer, H., Bargellini, I., Bartenstein, P., de Toni, E. N., Gasbarrini, A., Pech, M., Peck-Radosavljevic, M., Popovič, P., Rosmorduc, O., Schott, E., Seidensticker, M., Verslype, C., Sangro, B., & Malfertheiner, P.
Venue
Journal of Hepatology
Publisher
Elsevier BV
Published
2019-12
Volume
71
Issue
6
Pages
1164-1174
ISSN
0168-8278 (ISSN-L)
OpenAlex
W2968989098
Cited by
397
References
28
FWCI
25.75
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. https://app.cochat.ai/papers/10.1016/j.jhep.2019.08.006
The paper
Ricke, J., Klümpen, H. J., Amthauer, H., Bargellini, I., Bartenstein, P., de Toni, E. N., Gasbarrini, A., Pech, M., Peck-Radosavljevic, M., Popovič, P., Rosmorduc, O., Schott, E., Seidensticker, M., Verslype, C., Sangro, B., & Malfertheiner, P. (2019). Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. Journal of Hepatology. https://doi.org/10.1016/j.jhep.2019.08.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.